An Orally Bioavailable ENPP1-Selective Inhibitor Demonstrates Superior Immune Preservation Effects Over STING Agonists and Confers Anti-Tumor Efficacy in Combination With Other Therapies in Syngeneic Tumor Models
An Orally Bioavailable ENPP1-Selective Inhibitor Demonstrates Superior Immune Preservation Effects Over STING Agonists and Confers Anti-Tumor Efficacy in Combination With Other Therapies in Syngeneic Tumor Models
ENA – October 2022
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
